Display options
Cite
Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. IL-32α-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology. 2017;6(7):e1328338doi: 10.1080/2162402X.2017.1328338.
Catalán, V., Gómez-Ambrosi, J., Rodríguez, A., Ramírez, B., Ortega, V. A., Hernández-Lizoain, J. L., Baixauli, J., Becerril, S., Rotellar, F., Valentí, V., Moncada, R., Silva, C., Salvador, J., & Frühbeck, G. (2017). IL-32α-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology, 6(7), e1328338. https://doi.org/10.1080/2162402X.2017.1328338
Catalán, Victoria, et al. "IL-32α-induced inflammation constitutes a link between obesity and colon cancer." Oncoimmunology vol. 6,7 (2017): e1328338. doi: https://doi.org/10.1080/2162402X.2017.1328338
Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Ortega VA, Hernández-Lizoain JL, Baixauli J, Becerril S, Rotellar F, Valentí V, Moncada R, Silva C, Salvador J, Frühbeck G. IL-32α-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology. 2017 May 16;6(7):e1328338. doi: 10.1080/2162402X.2017.1328338. eCollection 2017. PMID: 28811968; PMCID: PMC5543901.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2017 May 16;6(7):e1328338. doi: 10.1080/2162402X.2017.1328338. eCollection 2017.

IL-32α-induced inflammation constitutes a link between obesity and colon cancer.

Oncoimmunology

Victoria Catalán, Javier Gómez-Ambrosi, Amaia Rodríguez, Beatriz Ramírez, Victor A Ortega, José Luis Hernández-Lizoain, Jorge Baixauli, Sara Becerril, Fernando Rotellar, Víctor Valentí, Rafael Moncada, Camilo Silva, Javier Salvador, Gema Frühbeck

Affiliations

  1. Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
  2. CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
  3. Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona, Spain.
  4. Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
  5. Department of Anesthesia, Clínica Universidad de Navarra, Pamplona, Spain.
  6. Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

PMID: 28811968 PMCID: PMC5543901 DOI: 10.1080/2162402X.2017.1328338

Abstract

Growing evidence indicates that adipose tissue inflammation is an important mechanism whereby obesity promotes cancer risk and progression. Since IL-32 is an important inflammatory and remodeling factor in obesity and is also related to colon cancer (CC) development, the aim of this study was to explore whether IL-32 could function as an inflammatory factor in human obesity-associated CC promoting a microenvironment favorable for tumor growth. Samples obtained from 84 subjects [27 lean (LN) and 57 obese (OB)] were used in the study. Enrolled subjects were further subclassified according to the established diagnostic protocol for CC (49 without CC and 35 with CC). We show, for the first time, that obesity (

Keywords: Adipose tissue; IL-32; colon cancer; inflammation; obesity

References

  1. J Natl Cancer Inst. 2017 Aug 1;109 (8): - PubMed
  2. Biochem Biophys Res Commun. 2011 Nov 18;415(2):245-51 - PubMed
  3. Cell. 2016 Jul 14;166(2):288-298 - PubMed
  4. J Immunol. 2014 Jan 15;192(2):589-602 - PubMed
  5. Cell Mol Life Sci. 2013 Oct;70(20):3883-92 - PubMed
  6. Immunity. 2005 Jan;22(1):131-42 - PubMed
  7. Clin Biochem. 2002 Jun;35(4):315-20 - PubMed
  8. Cell. 2010 Mar 19;140(6):883-99 - PubMed
  9. Diabetes Care. 2012 Feb;35(2):383-8 - PubMed
  10. Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii61-4 - PubMed
  11. Clin Cancer Res. 2014 May 1;20(9):2276-88 - PubMed
  12. BMC Med. 2012 Sep 25;10:108 - PubMed
  13. BMC Microbiol. 2015 Feb 21;15:39 - PubMed
  14. Oncogene. 2011 Jul 28;30(30):3345-59 - PubMed
  15. Nat Rev Endocrinol. 2014 Nov;10(11):644-5 - PubMed
  16. Nat Med. 2011 Oct 30;17(11):1498-503 - PubMed
  17. J Clin Oncol. 2016 Dec 10;34(35):4270-4276 - PubMed
  18. Gastroenterology. 2010 Jun;138(6):2101-2114.e5 - PubMed
  19. Lancet. 2014 Aug 30;384(9945):755-65 - PubMed
  20. J Immunol. 1992 Jan 15;148(2):597-603 - PubMed
  21. J Clin Invest. 2005 Jun;115(6):1492-502 - PubMed
  22. Int J Obes (Lond). 2012 Feb;36(2):286-94 - PubMed
  23. Cytokine. 2014 Jan;65(1):24-32 - PubMed
  24. Immunology. 2009 Apr;126(4):535-42 - PubMed
  25. JAMA. 2016 Jun 21;315(23):2576-94 - PubMed
  26. Nat Rev Cancer. 2013 Nov;13(11):759-71 - PubMed
  27. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3298-303 - PubMed
  28. Carcinogenesis. 2016 Feb;37(2):197-205 - PubMed
  29. Lancet. 2008 Feb 16;371(9612):569-78 - PubMed
  30. Obesity (Silver Spring). 2011 Jul;19(7):1439-44 - PubMed
  31. Gut. 2013 Jun;62(6):810-1 - PubMed
  32. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3515-20 - PubMed
  33. World J Gastroenterol. 2014 Apr 28;20(16):4586-96 - PubMed
  34. Obes Facts. 2013;6(2):117-20 - PubMed
  35. Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21082-6 - PubMed
  36. Diabetes. 2016 Dec;65(12 ):3636-3648 - PubMed
  37. BMC Cancer. 2012 Nov 23;12:545 - PubMed
  38. Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16309-14 - PubMed
  39. Cancer Lett. 2015 Jan 28;356(2 Pt B):800-8 - PubMed
  40. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  41. World J Surg Oncol. 2015 Apr 12;13:146 - PubMed
  42. Front Endocrinol (Lausanne). 2014 May 01;5:65 - PubMed
  43. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3316-21 - PubMed
  44. Clin Exp Immunol. 2007 Sep;149(3):480-6 - PubMed
  45. Am J Respir Crit Care Med. 2009 Oct 15;180(8):769-79 - PubMed
  46. J Clin Endocrinol Metab. 2011 Apr;96(4):E586-97 - PubMed
  47. Oncol Lett. 2015 Jan;9(1):305-307 - PubMed
  48. Cancer Res. 2011 Apr 1;71(7):2455-65 - PubMed
  49. Hepatology. 2011 Jun;53(6):1819-29 - PubMed
  50. Front Physiol. 2013 Oct 02;4:275 - PubMed
  51. Diabetologia. 2003 Feb;46(2):143-72 - PubMed
  52. PLoS One. 2016 Sep 09;11(9):e0162189 - PubMed
  53. Diabetes. 2015 Mar;64(3):856-66 - PubMed
  54. Science. 2005 Dec 2;310(5753):1504-10 - PubMed
  55. J Nutr Biochem. 2011 Jul;22(7):634-41 - PubMed
  56. J Biol Chem. 2012 Feb 17;287(8):5733-43 - PubMed
  57. Mol Carcinog. 2014 Feb;53 Suppl 1:E23-35 - PubMed
  58. Cancer Lett. 2011 Dec 15;312(1):62-72 - PubMed
  59. J Leukoc Biol. 2017 Jan;101(1):39-52 - PubMed
  60. Mediators Inflamm. 2016;2016:8413768 - PubMed
  61. Am J Physiol Endocrinol Metab. 2015 Oct 15;309(8):E691-714 - PubMed

Publication Types